Xin Lang Cai Jing·2025-11-07 07:38Core Viewpoint - The company, Junshi Biosciences, aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation in drug development [2][3]. Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020. Its main business involves the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with 90.67% of revenue coming from drug sales [7]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8]. Product Development - The company has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi Biosciences is also advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Collaborations and Research - The company is collaborating with institutions such as Peking University and the Chinese Academy of Sciences to develop vaccines, including a monkeypox vaccine, which is currently in the preclinical development stage [3][8]. Market Performance - On November 7, the company's stock fell by 1.92%, with a trading volume of 292 million yuan and a market capitalization of 38.799 billion yuan [1]. - The stock has seen a net outflow of 458.376 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 41.33 yuan, with the current price approaching a resistance level of 38.99 yuan, suggesting potential volatility in the near term [6].